Direct clearance of free virus and antibody-dependent cellular cytotoxicity of virus-infected cells appear to be the major mechanisms that contribute to the anti-viral effect of bavituximab
Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Bavituximab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Bavituximab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Bavituximab. |
| Estrone | Estrone may increase the thrombogenic activities of Bavituximab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Bavituximab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Bavituximab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Bavituximab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Bavituximab. |
| Estriol | Estriol may increase the thrombogenic activities of Bavituximab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Bavituximab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Bavituximab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Bavituximab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Bavituximab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bavituximab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bavituximab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Bavituximab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Bavituximab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Bavituximab. |
| Equol | Equol may increase the thrombogenic activities of Bavituximab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Bavituximab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Bavituximab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Bavituximab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Bavituximab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Bavituximab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Bavituximab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Bavituximab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Bavituximab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Bavituximab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Bavituximab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Bavituximab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Bavituximab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bavituximab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Bavituximab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Bavituximab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Bavituximab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bavituximab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bavituximab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Bavituximab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bavituximab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Bavituximab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Bavituximab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Bavituximab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bavituximab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bavituximab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Bavituximab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bavituximab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bavituximab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bavituximab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bavituximab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Bavituximab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Bavituximab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bavituximab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bavituximab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bavituximab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Bavituximab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Bavituximab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Bavituximab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Bavituximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Bavituximab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Bavituximab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Bavituximab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Bavituximab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Bavituximab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Bavituximab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Bavituximab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Bavituximab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Bavituximab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Bavituximab. |
| CR002 | The risk or severity of adverse effects can be increased when Bavituximab is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Bavituximab is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Bavituximab is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Bavituximab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Bavituximab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Bavituximab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Bavituximab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Bavituximab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Bavituximab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Bavituximab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Bavituximab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Bavituximab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Bavituximab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Bavituximab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Canakinumab. |